Intuitive Surgical Inc   (ISRG)
Other Ticker:  
Price: $221.6100 $2.54 1.159%
Day's High: $222.35 Week Perf: -1.59 %
Day's Low: $ 219.33 30 Day Perf: -12.18 %
Volume (M): 76 52 Wk High: $ 369.69
Volume (M$): $ 16,584 52 Wk Avg: $310.36
Open: $222.31 52 Wk Low: $206.60

 Market Capitalization (Millions $) 81,264
 Shares Outstanding (Millions) 367
 Employees 8,081
 Revenues (TTM) (Millions $) 5,906
 Net Income (TTM) (Millions $) 1,662
 Cash Flow (TTM) (Millions $) -300
 Capital Exp. (TTM) (Millions $) 390

Intuitive Surgical Inc
Intuitive Surgical, Inc. was founded in 1995. We are a Delaware corporation with our corporate headquarters located at 1266 Kifer Road, Sunnyvale, California 94086. Our telephone number is (408) 523-2100, and our website address is www.intuitivesurgical.com . In this report, “Intuitive Surgical,” “we,” “us,” and “our” refer to Intuitive Surgical, Inc. and its subsidiaries. Intuitive®, da Vinci®, da Vinci®S™, TilePro™, Solo Surgery™, EndoWrist®, InSite®, AESOP®, HERMES®, ZEUS®, SOCRATES™ and Navigator™ are trademarks of Intuitive Surgical, Inc.

We design, manufacture and market the da Vinci Surgical Systems, which are advanced surgical systems that we believe, represent a new generation of surgery. We believe that this new generation of surgery, which we call da Vinci surgery, is a revolutionary advancement similar in scope to previous generations of surgery—open surgery and minimally invasive surgery, or MIS. Our da Vinci Surgical Systems consist of a surgeon’s console, a patient-side cart, a high performance vision system and proprietary “wristed” instruments and surgical accessories. By placing computer-enhanced technology between the surgeon and patient, we believe that our systems enable surgeons to perform advanced MIS in a manner never before experienced. The da Vinci Surgical System controls Intuitive Surgical endoscopic instruments, including rigid endoscopes, blunt and sharp endoscopic dissectors, scissors, scalpels, forceps/pickups, needle holders, endoscopic retractors, electrocautery, ultrasonic cutters, and accessories during a wide range of surgical procedures. The da Vinci Surgical System seamlessly translates the surgeon’s natural hand movements on instrument controls at the console into corresponding micro-movements of instruments positioned inside the patient through small puncture incisions, or ports. Our da Vinci Surgical System provides the surgeon with the intuitive control, range of motion, fine tissue manipulation capability and 3-D vision characteristic of open surgery, while simultaneously allowing the surgeon to work through the small ports of MIS.

In March 1997, surgeons using an early prototype of our technology successfully performed the first da Vinci surgery on humans. In the second quarter of 1999, we began selling da Vinci products and services outside the United States. In July 2000, we obtained clearance from the U.S. Food and Drug Administration (FDA) to market our products in the United States for use in General laparoscopic procedures.

Our goal is to establish da Vinci surgery as the standard approach for complex surgical procedures, displacing both open surgical technique and standard MIS within this segment. We intend to accomplish this objective both by pioneering new types of endoscopic surgery and by making existing MIS procedures easier, safer and more cost-effective than the alternative methods. Our strategy is to broaden the number of procedures performed using the da Vinci Surgical System and to educate surgeons, hospitals and patients as to the benefits of da Vinci surgery.

Sales and Customer Support

We market our products through a direct sales force in the United States and parts of Europe. We also market our products outside the United States through distributors. Our direct sales force is comprised of sales managers, clinical sales representatives, training specialists, and technical service representatives. Sales activities include educating surgeons and hospital staff across multiple surgical specialties on the advantages of da Vinci surgery and the clinical applications that our technology enables. We also train our sales force to educate hospital management on the potential benefits of adopting our technology, including the potential for increased local market share that may result from offering da Vinci surgery. Once a hospital has installed a da Vinci Surgical System, our clinical sales representatives help drive the utilization of the system, and our technical service representatives provide service and maintenance for the system.


We consider our primary competition to be existing open surgery, MIS, drug therapies, radiation treatment and emerging interventional surgical approaches. Our success depends in part on convincing hospitals, surgeons and patients that the demonstrated benefits associated with da Vinci surgery are superior to other techniques. We also face competition from several companies that are developing new approaches and products for the MIS market. Because many of these developments are aimed at MIS, we believe that our da Vinci Surgical System may actually prove complementary to these new technologies.

In addition, a limited number of companies are using or planning to use robots and computers in surgery, including Armstrong Healthcare Ltd., Hitachi Ltd., MicroDexterity Systems, Inc., Sinters SA, Terumo Medical Corporation, and Toshiba, Inc. Our revenues may be reduced or eliminated if our competitors develop and market products that are more effective or less expensive than our products.

   Company Address: 1020 Kifer Road Sunnyvale 94086 CA
   Company Phone Number: 523-2100   Stock Exchange / Ticker: NASDAQ ISRG
   ISRG is expected to report next financial results on July 20, 2022.


Stock Performances by Major Competitors

Year to Date Decrease / Increase
DHR   -19.84%    
GE   -21.59%    
OSIS   -14.31%    
ROP   -10.75%    
TMO   -13.91%    
• View Complete Report

Sunworks Inc.

Deficit Bigger Than a Year Ago by Sunworks Inc in the first quarter of 2022 announcement

Sunworks Inc announced very strong Sales growth of 405.69% year on year to $31.20 millions in the first quarter of 2022, but loss increased at $-0.28.

Aixin Life International Inc.

Aixin Life International Inc reported exceptional results in the financial span ending Mar 31 2022

Aixin Life International Inc announced very strong Sales growth of 362.73% year on year to $0.42 millions in the financial span ending Mar 31 2022, but increased losses at $-0.02.

Aerovate Therapeutics Inc.

Logged a Loss but Revenues Unchanged at Aerovate Therapeutics Inc in the fiscal span ending Mar 31 2022

In the fiscal span ending Mar 31 2022 Aerovate Therapeutics Inc lost money of $-0.45 per share compared to $-1.87 a year ago and eps fell from $0.94 per share from the previous quarter.

Celsion Corporation

Losses Widen but Revenues Unchanged

In the financial period ending Mar 31 2022 Celsion Corporation increased losses of $-1.82 per share compared to $-0.08 a year ago and increased losses from $-0.02 per share from the previous quarter.

Forge Innovation Development Corp.

Very impressive jump in Sales at Forge Innovation Development Corp in the most recent fiscal period

In the most recent fiscal period Forge Innovation Development Corp reached break-even of $0.00 per share compared to $-0.01 a year ago and from $-0.00 per share from the previous quarter.


Intuitive Surgical Inc 's Segments
Instruments & accessories
 Segment    50.55 % of total Revenue
 Segment    29.54 % of total Revenue
Services & training
 Segment    19.91 % of total Revenue
• View Complete Report

Intuitive Surgical Inc 's Operating Statistics Decrease / Increase
• View Complete Report


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

IGTA's Profile

Stock Price

IGTA's Financials

Business Description


Charts & Quotes

IGTA's News


IGTA's Competitors

Customers & Markets

Economic Indicators

IGTA's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries






About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright Š 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071